Patents by Inventor Jiaxi WU

Jiaxi WU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240101633
    Abstract: The present disclosure provides interferon receptor agonists with improved safety profiles and therapeutic indices. The interferon receptor agonists are attenuated through masking and/or reduced receptor binding as compared to a wild-type interferon. IFN receptor agonists optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor- or immune cell-associated antigen and directs the interferon receptor agonist to a tumor site and/or tumor-reactive immune cells. The disclosure further provides pharmaceutical compositions comprising the interferon receptor agonists, and methods of use of the interferon receptor agonists in therapy, as well as nucleic acids encoding the interferon receptor agonists, recombinant cells that express the interferon receptor agonists and methods of producing the interferon receptor agonists.
    Type: Application
    Filed: August 18, 2023
    Publication date: March 28, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Eva-Maria WEICK, Nicolin BLOCH, Vidur GARG, Erica ULLMAN, Tong ZHANG, Chia-Yang LIN, Jiaxi WU, Eric Smith
  • Publication number: 20240067691
    Abstract: The present disclosure provides interferon receptor agonists with improved safety profiles and therapeutic indices. The interferon receptor agonists are attenuated through masking and/or reduced receptor binding as compared to a wild-type interferon. IFN receptor agonists optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor- or immune cell-associated antigen and directs the interferon receptor agonist to a tumor site and/or tumor-reactive immune cells. The disclosure further provides pharmaceutical compositions comprising the interferon receptor agonists, and methods of use of the interferon receptor agonists in therapy, as well as nucleic acids encoding the interferon receptor agonists, recombinant cells that express the interferon receptor agonists and methods of producing the interferon receptor agonists.
    Type: Application
    Filed: August 17, 2023
    Publication date: February 29, 2024
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Eva-Maria WEICK, Nicolin BLOCH, Vidur GARG, Erica ULLMAN, Tong ZHANG, Chia-Yang LIN, Jiaxi WU, Eric Smith
  • Publication number: 20240067690
    Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R??. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.
    Type: Application
    Filed: October 25, 2023
    Publication date: February 29, 2024
    Inventors: Jiaxi Wu, Tong Zhang, Samuel Davis, Nicolin Bloch
  • Publication number: 20230391844
    Abstract: The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2R? moiety and a protease-cleavable linker, configured such that the IL2R? moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.
    Type: Application
    Filed: June 2, 2023
    Publication date: December 7, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi WU, Supriya PATEL, Tong ZHANG, Nicolin BLOCH, Eric SMITH, Chia-Yang LIN, Vidur GARG, Erica ULLMAN
  • Patent number: 11834485
    Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R??. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: December 5, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi Wu, Tong Zhang, Samuel Davis, Nicolin Bloch
  • Publication number: 20230382969
    Abstract: The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2R? moiety and a protease-cleavable linker, configured such that the IL2R? moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.
    Type: Application
    Filed: May 26, 2023
    Publication date: November 30, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Supriya PATEL, Tong ZHANG, Jiaxi WU, Aaron CHANG, Eric SMITH, Chia-Yang LIN, Samuel DAVIS
  • Publication number: 20230331800
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Application
    Filed: May 9, 2023
    Publication date: October 19, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi WU, Tong ZHANG, Maria del Pilar MOLINA-PORTELA, Eric SMITH, Chia-Yang LIN, Thomas Craig MEAGHER
  • Publication number: 20230312665
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Application
    Filed: April 11, 2023
    Publication date: October 5, 2023
    Inventors: Jiaxi WU, Tong ZHANG, Maria del Pilar MOLINA-PORTELA, Eric SMITH, Chia-Yang LIN, Thomas Craig MEAGHER
  • Patent number: 11725034
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Grant
    Filed: March 31, 2022
    Date of Patent: August 15, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi Wu, Tong Zhang, Maria del Pilar Molina-Portela, Eric Smith, Chia-Yang Lin, Thomas Craig Meagher
  • Publication number: 20230110958
    Abstract: The present disclosure relates to IL27 receptor agonists with improved therapeutic profiles.
    Type: Application
    Filed: August 15, 2022
    Publication date: April 13, 2023
    Inventors: Arielle Glatman Zaretsky, Jiaxi Wu, Tong Zhang, Sokol Haxhinasto, Nicolin Bloch
  • Publication number: 20230053563
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Application
    Filed: June 17, 2022
    Publication date: February 23, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi WU, Tong ZHANG, Maria del Pilar MOLINA-PORTELA, Eric Smith, Chia-Yang LIN, Thomas Craig Meagher
  • Publication number: 20230051304
    Abstract: The present disclosure relates to IL12 receptor agonists with improved therapeutic profiles.
    Type: Application
    Filed: July 18, 2022
    Publication date: February 16, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Aaron CHANG, Jiaxi WU, Tong ZHANG, Nicolin BLOCH, Erica ULLMAN, Eric SMITH, Chia-Yang LIN, Samuel DAVIS
  • Publication number: 20220402989
    Abstract: The present disclosure relates to a fusion protein comprising an antigen-binding moiety that binds specifically to human PD-1 and an IL2 moiety, and methods of use thereof.
    Type: Application
    Filed: June 13, 2022
    Publication date: December 22, 2022
    Inventors: Jiaxi Wu, Nicolin Bloch, Tong Zhang, Chia-Yang Lin, Samuel Davis, Eric Smith, Erica Ullman
  • Publication number: 20220362395
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Application
    Filed: June 17, 2022
    Publication date: November 17, 2022
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi WU, Tong ZHANG, Maria del Pilar MOLINA-PORTELA, Eric Smith, Chia-Yang LIN, Thomas Craig Meagher
  • Patent number: 11492368
    Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: November 8, 2022
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zhijian Chen, Lijun Sun, Jiaxi Wu, Heping Shi, Chuo Chen
  • Publication number: 20220220182
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Application
    Filed: March 31, 2022
    Publication date: July 14, 2022
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi WU, Tong ZHANG, Maria del Pilar MOLINA-PORTELA, Eric SMITH, Chia-Yang LIN, Thomas Craig MEAGHER
  • Publication number: 20210324030
    Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R??. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.
    Type: Application
    Filed: April 20, 2021
    Publication date: October 21, 2021
    Inventors: Jiaxi Wu, Tong Zhang, Samuel Davis, Nicolin Bloch
  • Publication number: 20210188934
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi WU, Tong ZHANG, Maria del Pilar MOLINA-PORTELA, Eric SMITH, Chia-Yang LIN, Thomas Craig Meagher
  • Publication number: 20210187027
    Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi WU, Tong ZHANG, Maria del Pilar MOLINA-PORTELA, Eric SMITH, Chia-Yang LIN, Thomas Craig MEAGHER
  • Publication number: 20200308216
    Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Zhijian CHEN, Lijun SUN, Jiaxi WU, Heping SHI, Chuo CHEN